Single B cell antibody discovery is the latest monoclonal antibody discovery technology. This technology combines single cell isolation and identification technology with high-throughput sequencing technology, and takes a single B cell as the starting point to quickly obtain antigen-specific antibodies. DetaiBio SingleB® antibody development technology is applicable to many animal species, with high antibody discovery efficiency and high processing throughput. The obtained antibody is naturally mature in vivo and has rich genetic diversity, which can provide more candidate antibody molecules for the development of antibody drugs.
DetaiBio provides Mouse SingleB® mAb Discovery Service. From animal immunization to obtaining monoclonal antibodies, the whole process is fast up to 29 days, which is at least 120 days less than the traditional hybridoma technology, ensuring FACS binding and sequence diversity.
Whole process only takes 29 days
100 days less than hybridoma
Deliver 50 FACS binders
Ensure sequence diversity
double screening, double guarantee
|Stage Ⅰ Animal Immunization||29 days|| Premium Package|
|Stage Ⅱ “1+1”Double Screening|
|Stage Ⅲ BGE® HTP Expression & Functional Test|
|Stage Ⅳ Monoclonal Antibody Gene Sequencing|
|Stage Ⅴ Expression and Purification of Recombinant Antibody (optional)||For enquiry|
Specific MBC Screening
Specific memory B cells were screened by cell surface marker and antigen.
Specific PBC HTP Screening
With DeepLight® On-chip Cell Screening Platform，peform binding-blocking function screening to obtain specific plasma cells.
Antibody Functional Verification
The obtained antibodies were tested by ELISA and FACS assay.
Antibody Diversity Analysis
The obtained antibodies are analyzed for V-region diversity, and the gene tree can be further constructed according to needs, so that users can easily select antibodies with good drug properties.